Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immatics (IMTX)
NASDAQ:IMTX
Holding IMTX?
Track your performance easily
IMTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.27 - $13.77
Previous CloseN/A
Volume408.80K
Average Volume (3M)956.92K
Market Cap
$668.39M
Enterprise Value$663.37M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Mar 19, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding119,355,900
10 Day Avg. Volume1,022,909
30 Day Avg. Volume956,922
Standard Deviation0.14
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.43
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue20.55
Enterprise Value/Gross Profit12.29
Enterprise Value/Ebitda-22.84
Forecast
1Y Price Target
$16.58Price Target Upside210.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Immatics News
PremiumCompany Announcements
Immatics Advances PRAME Cell Therapy and Expands Oncology PipelinePremiumCompany Announcements
Immatics Faces Termination of Key Collaboration with Bristol Myers SquibbPremiumCompany Announcements
Immatics N.V. Reports Strong Q3 2024 Progress and Financials
Bulls Say, Bears Say
Bulls Say
Clinical Data And ResearchImpressive data was reported for IMA203, with a 62% overall response rate and a 92% disease control rate in a heavily pre-treated metastatic melanoma patient group.
Financial PositionIMTX has a strong cash position with a financial runway into the second half of 2027.
Partnerships And CollaborationsImmatics N.V. continues to have ongoing partnerships with Editas Medicine and Moderna Therapeutics, which investors may view as an important source of external validation.
Bears Say
Efficacy DataEfficacy data on tumor types with larger commercial opportunities, such as ovarian, endometrial, and lung cancers, remain limited.
Partnership TerminationThe termination by Bristol Myers Squibb of a collaboration with Immatics N.V. is seen as an incremental negative for the stock.
Safety ConcernsOne possible Grade 5 treatment-related adverse event of fatal sepsis was disclosed, highlighting a severe safety concern.
---
Ownership Overview
―
Insiders
11.44% Mutual Funds
47.53% Other Institutional Investors
40.83% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMTX FAQ
What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was $5.27 and its highest was $13.77 in the past 12 months.
What is Immatics’s market cap?
Immatics’s market cap is $668.39M.
When is Immatics’s upcoming earnings report date?
Immatics’s upcoming earnings report date is Mar 19, 2025 which is in 49 days.
How were Immatics’s earnings last quarter?
Immatics released its earnings results on Nov 18, 2024. The company reported -$0.115 earnings per share for the quarter, beating the consensus estimate of -$0.262 by $0.147.
Is Immatics overvalued?
According to Wall Street analysts Immatics’s price is currently Undervalued.
Does Immatics pay dividends?
Immatics does not currently pay dividends.
What is Immatics’s EPS estimate?
Immatics’s EPS estimate is -0.29.
How many shares outstanding does Immatics have?
Immatics has 119,355,900 shares outstanding.
What happened to Immatics’s price movement after its last earnings report?
Immatics reported an EPS of -$0.115 in its last earnings report, beating expectations of -$0.262. Following the earnings report the stock price went down -4.284%.
Which hedge fund is a major shareholder of Immatics?
Among the largest hedge funds holding Immatics’s share is Perceptive Advisors LLC. It holds Immatics’s shares valued at 92M.
---
Immatics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.58 (210.49% Upside)
$16.58 (210.49% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 760.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.89%
12-Months-Change
Fundamentals
Return on Equity
-14.59%
Trailing 12-Months
Asset Growth
39.10%
Trailing 12-Months
Company Description
Immatics
Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.
---
IMTX Stock 12 Month Forecast
Average Price Target
$16.58
▲(210.49% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering IMTX
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-15.47%
reiterated a buy rating last month
Copying Graig Suvannavejh's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -15.47% per trade.
---